| |||
Drug Found to Curb Kids' Debilitating Social Anxiety
Washington Post Staff Writer Thursday, April 26, 2001; Page A01 Children who are so shy or so attached to their parents that they are
afraid to go to school or sleep alone do much better when given a
psychiatric drug, according to a major study with profound -- and
controversial -- ramifications for millions of children. The study of 128 children ages 6 to 17 found that the drug Luvox,
widely prescribed for adults with depression, alleviated the debilitating
symptoms of social phobia, separation anxiety and generalized anxiety --
psychiatric illnesses that afflict as many as 1 in 10 U.S. children. The effects of the medicine were dramatic, but experts were divided
about its appropriateness: The medicine can help children with severe
emotional problems, but it might also be abused as a chemical quick fix
for normal anxiousness, with lasting effects on growing brains. "Although the results seem impressive, they nevertheless raise some
very important questions about the use of psychotropic medications in
children," said Joseph Coyle, chairman of psychiatry at Harvard Medical
School, in an article accompanying the findings in today's New England
Journal of Medicine. "Any drug that is effective is not going to be innocuous," he said in
an interview. Children and adolescents diagnosed with these disorders
should first try a form of therapy known as cognitive behavioral therapy,
and turn to medication only if that fails, he said. An estimated 575,000 children nationwide were diagnosed with anxiety
disorders in the 12 months ending in March, including 136,000 under age
10. Doctors recommended 390,000 children be put on medicines such as
Zoloft, Paxil and Prozac. Of these, 89,000 were under age 10, according to
IMS Health, a private company that tracks the pharmaceutical industry. Such vast numbers leave critics aghast. Too many children are being put
on powerful brain-altering drugs for behaviors that may be merely
troublesome, critics say. But other experts point out that many children
suffer from distress that, left untreated, can cause impairment well into
adulthood. "Researchers found that anxiety was among the most common problems that
kids have," said Daniel Pine of the National Institute of Mental Health.
He led the study. "When researchers follow children with anxiety over
time, sometimes anxiety developed into more chronic problems. It could be
the harbinger of problems with depression, panic attacks and all different
kinds of problems." The study, the first large, well-designed survey to examine the
effectiveness of a psychiatric drug for a wide range of anxiety disorders
in children, was partly funded by the National Institute of Mental Health
and by Solvay Pharmaceuticals, which sells Luvox. The drug, which like
Prozac increases levels of the brain chemical serotonin, has been approved
for the treatment of obsessive compulsive disorder in children. Luvox
sales were more than $2 billion in the United States last year, according
to IMS Health. Scientists at Johns Hopkins University, Columbia University, New York
University, Duke University and the University of California at Los
Angeles studied the drug over eight weeks in children with anxiety
disorders. An example of a child with severe social phobia would be one who
refused to go to school for two weeks, said Mark Riddle of the Johns
Hopkins University School of Medicine, one of the study's authors. A
milder example, he said, would be a child who went to school and
participated in clubs and group events, but with intense discomfort. Extreme separation anxiety disorder, he said, would be displayed in a
child who avoided birthday parties and sleepovers. A medium-grade example
would be children who refused to sleep in their own rooms and wanted to
get into bed with their parents. Generalized anxiety disorder, Riddle said, were "the worrywarts." "A lot of it would be about performance -- getting very preoccupied
with a test at school, a lot of fussing about day-to-day things," he
said. "We don't want a Prozac nation," he said about the medication of
children. "We want to make sure we are not doing anything to harm
youngsters. On the other hand, it can be a huge disservice to children to
minimize the true significance of psychiatric impairments that do require
treatments. It's the latter that can get lost in the very easy and popular
position to take, which is 'Don't drug our kids.' " Richard Harding, president-elect of the American Psychiatric
Association, said clinicians should carefully evaluate anxious children to
find out whether their fears are caused by an underlying personality
problem -- which would merit psychotherapy or medication -- or by a social
problem, such as a bully in school or child abuse at home, in which case
medication would be inappropriate. "A good clinician will not commit a child to a life sentence on
medicine," said Riddle. "A good clinician will look to stop medication
after the youngster has had a chance to regroup. You want to work with a
clinician who says we are going to get John off this medication." It is unclear what impact this study will have in clinical practice,
where doctors are prescribing children such medicines "off-label" --
meaning they have not been approved for such uses by the Food and Drug
Administration. "Given our current medical-economic system in practice, I suspect both
doctors and parents will be strongly attracted to the quick-fix nature of
this intervention," said Lawrence Diller, a behavioral pediatrician in
Walnut Creek, Calif., and the author of "Running on Ritalin." "We have highly effective psychosocial interventions for these
problems," he said. But "they are more expensive and take longer." He said that helping families come up with parenting strategies could
ease children's anxieties. "Children are highly responsive to their
environments, and the home is the practice arena to deal with life," he
said. "This is not parent-blaming -- children are difficult to raise. But
when the parent makes changes, you see very rapid changes in the
child." "It doesn't negate the value of the medications," he added. But "with
uncertainty on both sides, effective psychosocial treatments -- first do
no harm -- take preference." More extreme critics, such as Bethesda psychiatrist Peter Breggin, said
the study was produced by scientists who are part of an "old boys' network
of drug pushers." He said the psychiatric drugs cause harm -- some data
have shown that the drugs cause lasting alterations in the brains of young
animals. Researchers involved in the new study said the drug was well tolerated
and safe.
Related Links More Health News Full Coverage More Science News |
||||||||||||||||||||||||||||||||||||